(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 0.63% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3,789.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,551.19%.
Teva Pharmaceutical Industries's revenue in 2026 is $17,258,000,000.On average, 7 Wall Street analysts forecast TEVA's revenue for 2026 to be $19,967,650,786,668, with the lowest TEVA revenue forecast at $18,840,834,146,628, and the highest TEVA revenue forecast at $20,888,650,917,966.
In 2027, TEVA is forecast to generate $20,301,096,527,088 in revenue, with the lowest revenue forecast at $19,017,905,332,920 and the highest revenue forecast at $21,233,594,787,366.